Medicine‐related beliefs predict attribution of symptoms to a sham medicine: A prospective study. Issue 2 (5th February 2018)

• Record Type: Journal Article
• Authors: Webster, Rebecca K.; Weinman, John; Rubin, G. James
• Is Part Of: British journal of health psychology. Volume 23:Issue 2(2018)
• Page Start: 436
• Page End: 454
• Publication Date: 2018-02-05
• Subjects: nocebo effect -- placebo -- predictors -- medicine beliefs -- symptom attribution; Clinical health psychology -- Periodicals; 613.019
• DOI: 10.1111/bjhp.12298
• Languages: English
• ISSNs: 1359-107X

Abstract

Abstract : Objectives: To investigate a range of possible predictors of nocebo responses to medicines. Design: Prospective cohort study. Methods: In total, 203 healthy adult volunteers completed measures concerning demographics, psychological factors, medicine‐related beliefs, baseline symptoms, and symptom expectations before taking a sham pill, described as 'a well‐known tablet available without prescription' that was known to be associated with several side effects. Associations between these measures and subsequent attribution of symptoms to the tablet were assessed using a hurdle model consisting of a joint logistic and truncated negative binomial regression. Results: Men had an increased odds of attributing symptoms to the tablet OR = 1.52, and older participants had decreased odds, OR = 0.97. Medicine‐related beliefs were important, with modern health worries, belief that medicines cause harm and perceived sensitivity to medicines associated with increased odds of symptom attribution, OR = 1.02, 1.10, 1.09, respectively. Trust in medicines and pharmaceutical companies decreased the odds of symptom attribution, OR = 0.91, 0.88, respectively. The number of symptoms at baseline and the expected likelihood of symptoms were associated with an increased odds of attributing symptoms to the tablet, OR = 1.07, 1.06, respectively. Anxiety, previous symptom experience, symptom expectations, and modern health worries were also important in predicting the number of symptoms participants attributed to the tablet. Conclusion: It is hard to predict who is at risk of developing nocebo responses to medicines from demographic or personality characteristics. Context‐specific factors such as beliefs about and trust in medicines, current symptoms and symptom expectations are more useful as predictors. More work is needed to investigate this in a patient sample. Statement of contribution What is already known on this subject? Many patients report non‐specific side effects to their medication which may arise through a nocebo effect. Whether some people are particularly predisposed to experience nocebo effects remains unclear. What does this study add? Demographic and personality characteristics are poor predictors of symptom attribution to a sham medicine. Instead, context‐specific factors that concern people's beliefs surrounding medicines, their current symptoms, and symptom expectations are more useful as predictors of symptom attribution.